MPO and synovial sarcoma: In addition, montelukast, a CysLT1 receptor antagonist, was already shown to inhibit MPO activity, a neutrophilic-infiltration marker, in the liver of LPS-treated rats [54], and higher MPO concentrations appear to be related to SS patients’ mortality [76].